Terns Pharmaceuticals Acquired by Merck, Share Price Surges
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 08 2026
0mins
Should l Buy TERN?
Source: Fool
- Acquisition Agreement: On March 25, Terns Pharmaceuticals announced a definitive agreement with Merck, under which Merck will acquire Terns for $53 per share in cash, totaling approximately $6.7 billion, representing a 42% premium that significantly boosted Terns' share price by over 25% in March.
- Core Drug Value: Terns' lead drug candidate, TERN-701, is currently in a phase 1/2 clinical trial and has received FDA Orphan Drug Designation, which is expected to become a major revenue driver, enhancing the strategic significance of the acquisition.
- Positive Market Reaction: Analysts view the acquisition as a “steal” for Merck, as TERN-701 has the potential to be a strong revenue source, thereby strengthening Merck's position in oncology.
- Shareholder Benefit Assurance: Although the deal requires approval from a majority of Terns' shareholders, the substantial premium makes it likely to close within the current quarter, ensuring Terns' shareholders receive a healthy return.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TERN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TERN
Wall Street analysts forecast TERN stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.650
Low
35.00
Averages
54.22
High
60.00
Current: 52.650
Low
35.00
Averages
54.22
High
60.00
About TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its product candidates in pipeline includes TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic dysfunction-associated steatohepatitis (MASH). It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation: Halper Sadeh LLC is investigating companies such as Terns Pharmaceuticals, Inc., Soleno Therapeutics, Inc., and Whitestone REIT for potential violations of federal securities laws or breaches of fiduciary duties, highlighting concerns for investor rights.
- Transaction Price Analysis: Both Terns Pharmaceuticals and Soleno Therapeutics are being acquired at $53.00 per share, while Whitestone REIT is being sold for $19.00 per share or unit, suggesting these prices may not reflect the companies' true values, potentially leading to investor losses.
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options, committing to handle related matters at no upfront cost, aiming to provide legal support for affected investors.
- Legal Fee Arrangement: The firm states it will operate on a contingency fee basis, meaning shareholders will not be responsible for upfront legal fees and expenses, thereby reducing the legal risk for investors.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating Whitestone REIT (NYSE:WSR) for its sale to Ares Management Corporation at $19.00 per share, potentially violating fiduciary duties to shareholders and impacting their rights.
- Transaction Details: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is being sold to Merck for $53.00 per share in cash, with Halper Sadeh LLC suggesting that terms may limit superior competing offers, urging shareholders to be aware of their rights.
- Merger Impact: The merger of Rallybio Corporation (NASDAQ:RLYB) with Candid Therapeutics, Inc. is expected to result in Rallybio shareholders owning approximately 3.65% of the combined entity, prompting Halper Sadeh LLC to seek increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC offers no-cost legal consultations aimed at securing additional rights for investors affected by securities fraud and corporate misconduct, highlighting their commitment to protecting investor interests.
See More
Terns Pharmaceuticals Acquired by Merck, Share Price Surges
- Acquisition Agreement: On March 25, Terns Pharmaceuticals announced a definitive agreement with Merck, under which Merck will acquire Terns for $53 per share in cash, totaling approximately $6.7 billion, representing a 42% premium that significantly boosted Terns' share price by over 25% in March.
- Core Drug Value: Terns' lead drug candidate, TERN-701, is currently in a phase 1/2 clinical trial and has received FDA Orphan Drug Designation, which is expected to become a major revenue driver, enhancing the strategic significance of the acquisition.
- Positive Market Reaction: Analysts view the acquisition as a “steal” for Merck, as TERN-701 has the potential to be a strong revenue source, thereby strengthening Merck's position in oncology.
- Shareholder Benefit Assurance: Although the deal requires approval from a majority of Terns' shareholders, the substantial premium makes it likely to close within the current quarter, ensuring Terns' shareholders receive a healthy return.
See More
TERNS PHARMACEUTICALS INC: WILLIAM BLAIR LOWERS RATING TO MARKET PERFORM
Market Performance: Terns Pharmaceuticals, led by CEO William Blair, has reported a significant cut in its market performance rating.
Impact on Investors: The downgrade may affect investor confidence and the company's stock value moving forward.
See More
Merck Initiates Cash Tender Offer for Terns Pharmaceuticals
- Acquisition Offer Launched: Merck has officially initiated a cash tender offer today through its subsidiary to acquire all outstanding shares of Terns Pharmaceuticals, indicating its aggressive expansion strategy in the biopharmaceutical sector.
- Acquisition Price Set: Terns shareholders will receive $53.00 per share in cash for validly tendered shares, reflecting Merck's recognition of Terns' value and commitment to enhancing its portfolio.
- Transaction Timeline: The tender offer is set to expire at 11:59 p.m. Eastern Time on May 4, 2026, unless extended, with the transaction expected to close in the second quarter of 2026, showcasing Merck's proactive approach to mergers and acquisitions.
- Strategic Implications: This acquisition not only strengthens Merck's product lineup ahead of the Keytruda patent cliff but also potentially brings Terns' promising CML drug candidate into its portfolio, further solidifying its market position.
See More
MERCK INITIATES TENDER OFFER TO PURCHASE TERNS PHARMACEUTICALS, INC.
Merck's Acquisition Move: Merck has initiated a tender offer to acquire Terns Pharmaceuticals, Inc., signaling a strategic expansion in its pharmaceutical portfolio.
Focus on Innovation: The acquisition aims to enhance Merck's capabilities in developing innovative therapies, particularly in the field of oncology and other therapeutic areas.
Financial Details: The tender offer is part of Merck's ongoing strategy to invest in promising biotech firms that align with its long-term growth objectives.
Market Impact: This move is expected to influence the pharmaceutical market dynamics, potentially leading to increased competition and innovation in drug development.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation: Halper Sadeh LLC is investigating companies such as Terns Pharmaceuticals, Inc., Soleno Therapeutics, Inc., and Whitestone REIT for potential violations of federal securities laws or breaches of fiduciary duties, highlighting concerns for investor rights.
- Transaction Price Analysis: Both Terns Pharmaceuticals and Soleno Therapeutics are being acquired at $53.00 per share, while Whitestone REIT is being sold for $19.00 per share or unit, suggesting these prices may not reflect the companies' true values, potentially leading to investor losses.
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options, committing to handle related matters at no upfront cost, aiming to provide legal support for affected investors.
- Legal Fee Arrangement: The firm states it will operate on a contingency fee basis, meaning shareholders will not be responsible for upfront legal fees and expenses, thereby reducing the legal risk for investors.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Investigation Background: Halper Sadeh LLC is investigating Whitestone REIT (NYSE:WSR) for its sale to Ares Management Corporation at $19.00 per share, potentially violating fiduciary duties to shareholders and impacting their rights.
- Transaction Details: Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is being sold to Merck for $53.00 per share in cash, with Halper Sadeh LLC suggesting that terms may limit superior competing offers, urging shareholders to be aware of their rights.
- Merger Impact: The merger of Rallybio Corporation (NASDAQ:RLYB) with Candid Therapeutics, Inc. is expected to result in Rallybio shareholders owning approximately 3.65% of the combined entity, prompting Halper Sadeh LLC to seek increased compensation for shareholders.
- Legal Support: Halper Sadeh LLC offers no-cost legal consultations aimed at securing additional rights for investors affected by securities fraud and corporate misconduct, highlighting their commitment to protecting investor interests.
See More
Terns Pharmaceuticals Acquired by Merck, Share Price Surges
- Acquisition Agreement: On March 25, Terns Pharmaceuticals announced a definitive agreement with Merck, under which Merck will acquire Terns for $53 per share in cash, totaling approximately $6.7 billion, representing a 42% premium that significantly boosted Terns' share price by over 25% in March.
- Core Drug Value: Terns' lead drug candidate, TERN-701, is currently in a phase 1/2 clinical trial and has received FDA Orphan Drug Designation, which is expected to become a major revenue driver, enhancing the strategic significance of the acquisition.
- Positive Market Reaction: Analysts view the acquisition as a “steal” for Merck, as TERN-701 has the potential to be a strong revenue source, thereby strengthening Merck's position in oncology.
- Shareholder Benefit Assurance: Although the deal requires approval from a majority of Terns' shareholders, the substantial premium makes it likely to close within the current quarter, ensuring Terns' shareholders receive a healthy return.
See More
TERNS PHARMACEUTICALS INC: WILLIAM BLAIR LOWERS RATING TO MARKET PERFORM
Market Performance: Terns Pharmaceuticals, led by CEO William Blair, has reported a significant cut in its market performance rating.
Impact on Investors: The downgrade may affect investor confidence and the company's stock value moving forward.
See More
Merck Initiates Cash Tender Offer for Terns Pharmaceuticals
- Acquisition Offer Launched: Merck has officially initiated a cash tender offer today through its subsidiary to acquire all outstanding shares of Terns Pharmaceuticals, indicating its aggressive expansion strategy in the biopharmaceutical sector.
- Acquisition Price Set: Terns shareholders will receive $53.00 per share in cash for validly tendered shares, reflecting Merck's recognition of Terns' value and commitment to enhancing its portfolio.
- Transaction Timeline: The tender offer is set to expire at 11:59 p.m. Eastern Time on May 4, 2026, unless extended, with the transaction expected to close in the second quarter of 2026, showcasing Merck's proactive approach to mergers and acquisitions.
- Strategic Implications: This acquisition not only strengthens Merck's product lineup ahead of the Keytruda patent cliff but also potentially brings Terns' promising CML drug candidate into its portfolio, further solidifying its market position.
See More
MERCK INITIATES TENDER OFFER TO PURCHASE TERNS PHARMACEUTICALS, INC.
Merck's Acquisition Move: Merck has initiated a tender offer to acquire Terns Pharmaceuticals, Inc., signaling a strategic expansion in its pharmaceutical portfolio.
Focus on Innovation: The acquisition aims to enhance Merck's capabilities in developing innovative therapies, particularly in the field of oncology and other therapeutic areas.
Financial Details: The tender offer is part of Merck's ongoing strategy to invest in promising biotech firms that align with its long-term growth objectives.
Market Impact: This move is expected to influence the pharmaceutical market dynamics, potentially leading to increased competition and innovation in drug development.
See More
